Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

DOCS PEER ANALYSIS

Doximity Inc — metric-by-metric comparison with peers and the industry median

DOCSDoximity Inc

🇺🇸 USA · NYSE · Healthcare · Health Information Services

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Health Information Services

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
DOCSIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
DOCS-63.1%PME-31.5%FONET+128.7%
Year-to-Date (YTD)
DOCS-50.6%PME-4.8%FONET+88.2%
1-Year
Split-adjusted
DOCS-63.1%WAY-39.3%TXG+199.8%SLGC—PRVA+24.8%HQY-5.9%
Year-to-Date (YTD)
DOCS-50.6%WAY-28.4%TXG+139.2%SLGC-2.7%PRVA+15.4%HQY+4.0%

Key Metric Comparison

P/E

Lower is better
DOCS21.75PME93.49FONET20.21Median 41.96

ROE

Higher is better
DOCS19.3%PME76.8%FONET15.6%Median 2.7%

Net Margin

Higher is better
DOCS30.4%PME97.6%FONET26.0%Median 1.5%

Revenue Growth

Higher is better
DOCS13.1%PME30.3%FONET53.5%Median 7.1%

P/E

Lower is better
DOCS21.75WAY36.31TXG—SLGC—PRVA164.54HQY35.12Median 41.96

ROE

Higher is better
DOCS19.3%WAY3.6%TXG-3.0%SLGC-23.7%PRVA3.1%HQY11.1%Median 2.7%

Net Margin

Higher is better
DOCS30.4%WAY10.9%TXG-3.5%SLGC-159.5%PRVA1.0%HQY17.3%Median 1.5%

Revenue Growth

Higher is better
DOCS13.1%WAY18.6%TXG2.3%SLGC-19.7%PRVA24.7%HQY7.6%Median 7.1%

All Metrics

Valuation
MetricDOCSPMEFONETInd. Median
P/E21.7593.4920.21●41.96
P/B4.4856.422.62●2.50
EV/EBITDA13.25115.2410.38●16.12
P/S6.6191.215.26●2.35
Financial Health
MetricDOCSPMEFONETInd. Median
Current Ratio6.096.22●2.311.83
Debt/Equity1.1%●1.1%2.5%22.0%
NetDebt/EBITDA-2.78●-1.16-0.21-0.01
Profitability
MetricDOCSPMEFONETInd. Median
Net Margin30.4%97.6%●26.0%1.5%
ROE19.3%76.8%●15.6%2.7%
ROA16.4%56.7%●13.2%1.4%
EBITDA Margin41.3%78.4%●49.6%12.4%
Growth + Dividend
MetricDOCSPMEFONETInd. Median
Rev. Growth13.1%30.3%53.5%●7.1%
NI Growth-12.2%138.8%●26.6%23.6%
Div. Yield—0.3%●0.0%0.7%
Payout—24.5%0.0%9.6%
Valuation
MetricDOCSWAYTXGSLGCPRVAHQYInd. Median
P/E21.75●36.31——164.5435.1241.96
P/B4.481.16●6.157.284.763.962.50
EV/EBITDA13.25●14.2748.73—56.2319.2416.12
P/S6.613.967.8344.221.59●6.062.35
Financial Health
MetricDOCSWAYTXGSLGCPRVAHQYInd. Median
Current Ratio6.091.765.9017.79●1.613.441.83
Debt/Equity1.1%37.7%10.0%0.6%●1.2%48.1%22.0%
NetDebt/EBITDA-2.783.21-4.913.31-7.28●1.57-0.01
Profitability
MetricDOCSWAYTXGSLGCPRVAHQYInd. Median
Net Margin30.4%●10.9%-3.5%-159.5%1.0%17.3%1.5%
ROE19.3%●3.6%-3.0%-23.7%3.1%11.1%2.7%
ROA16.4%●2.4%-2.4%-20.8%1.7%6.9%1.4%
EBITDA Margin41.3%●35.8%14.6%-166.7%2.5%34.3%12.4%
Growth + Dividend
MetricDOCSWAYTXGSLGCPRVAHQYInd. Median
Rev. Growth13.1%18.6%2.3%-19.7%24.7%●7.6%7.1%
NI Growth-12.2%383.6%●——39.3%89.4%23.6%
Div. Yield——————0.7%
Payout——————9.6%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on DOCS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.